ALDX — Aldeyra The
NASDAQ · Healthcare · Biotechnology
$1.49
+$0.01 (+0.68%)
Aldeyra The (ALDX) is a biotechnology company listed on NASDAQ. It is led by Todd C. Brady M.D., Ph.D., based in 131 Hartwell Avenue, Lexington, MA, United States, 02421, with about 7 employees. Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Net income was -$27.4M. ALDX currently screens at market cap $112.2M.
Use this ALDX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ALDX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ALDX SEC filings page. Lician reads the product cache first so this HTML stays unique to Aldeyra The even when a live quote feed is slow.
About Aldeyra The
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Key Statistics
Market Cap
$112.20M
Volume
513,936
Previous Close
$1.52
Day Range
$1.46 – $1.54
EPS
-$0.94
Revenue
$0.00
Net Income
-$55.85M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
7
ALDX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$55.85M | -$37.54M | -$62.02M | -$57.78M |
| EPS (Diluted) | -$0.94 | -$0.64 | -$1.06 | -$1.07 |
Total Assets
$104.61M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$54.53M
Operating Cash Flow
-$43.21M
Free Cash Flow
$0.00
Aldeyra The Company Information
- CEO, President & Director
- Todd C. Brady M.D., Ph.D.
- Headquarters
- 131 Hartwell Avenue, Lexington, MA, United States, 02421
- Website
- www.aldeyra.com
- Phone
- 781 761 4904
- IPO / Founded
- 2014-05-02
- Sector
- Healthcare
- Industry
- Biotechnology